Furthermore, several studies have demonstrated that HSP90AA1 inhibitors decrease VEGF secretion from cancer cells, impair endothelial cell tubule formation in vitro, and reduce tumor size and vascularization in vivo [46, 47]. This evidence concerns the gene VEGFA and neoplasm.